Mira Pharmaceuticals (MIRA) Research & Development (2022 - 2025)
Mira Pharmaceuticals (MIRA) posted Research & Development of $496543.0 for Q4 2025, up 20.33% sequentially from $412639.0 in Q3 2025, and down 42.36% YoY from $861441.0 in Q4 2024.
Mira Pharmaceuticals (MIRA) Research & Development (2022 - 2025) Analysis & Trends
Mira Pharmaceuticals has reported Research & Development for 4 years, with the latest figure at $496543.0 in Q4 2025.
- Quarterly Research & Development fell 42.36% year-over-year to $496543.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.7 million (down 47.97% YoY) and the FY2025 annual result came in at $1.7 million, down 47.97% from the prior year.
- Research & Development climbed to $496543.0 in Q4 2025 per MIRA's latest filing, from $412639.0 in the prior quarter.
- Over five years, Research & Development peaked at $1.1 million in Q3 2024 and troughed at $271606.0 in Q1 2023.
- A 4-year average of $638389.5 and a median of $614462.0 in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2024 and 2025: Research & Development surged 180.66% in 2024, then sank 61.34% in 2025.
- Over 4 years, Research & Development stood at $884757.0 in 2022, then plunged by 56.25% to $387123.0 in 2023, then surged by 122.52% to $861441.0 in 2024, then slumped by 42.36% to $496543.0 in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $496543.0, $412639.0, and $496197.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 2.85 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 4.05 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -4.65 Bn |
| 10 | Mira Pharmaceuticals | 18.47 Mn | 7.44 Mn | - | 496,543.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 496,543.00 |
| Sep 30, 2025 | 412,639.00 |
| Jun 30, 2025 | 496,197.00 |
| Mar 31, 2025 | 314,404.00 |
| Dec 31, 2024 | 861,441.00 |
| Sep 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 614,462.00 |
| Mar 31, 2024 | 762,276.00 |
| Dec 31, 2023 | 387,123.00 |
| Sep 30, 2023 | 1.02 Mn |
| Mar 31, 2023 | 271,606.00 |
| Dec 31, 2022 | 884,757.00 |
| Sep 30, 2022 | 714,968.00 |